MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
XOMA Corporation Total Liabilities 2011-2026 | XOMA
Annual Total Liabilities XOMA Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 169 M | 139 M | 146 M | 16.4 M | 24.7 M | 38.9 M | 51.7 M | 45 M | 39.1 M | 75.9 M | 77.2 M | 86.5 M | 139 M | 84.2 M | 63 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 169 M | 16.4 M | 79.7 M |
Quarterly Total Liabilities XOMA Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 155 M | 131 M | 128 M | 139 M | 139 M | 143 M | - | 146 M | 18.1 M | 15.5 M | 19.1 M | 16.4 M | 15.8 M | - | 19.2 M | 24.7 M | 18.9 M | 19.2 M | 38.2 M | 38.9 M | 38.9 M | 38.9 M | 38.9 M | 51.7 M | 51.7 M | 51.7 M | 51.7 M | 45 M | 45 M | 45 M | 45 M | 39.1 M | 39.1 M | 39.1 M | 39.1 M | 75.9 M | 75.9 M | 75.9 M | 75.9 M | 77.2 M | 77.2 M | 77.2 M | 77.2 M | 86.3 M | 86.3 M | 86.3 M | 86.3 M | 139 M | 139 M | 139 M | 139 M | 84.2 M | 84.2 M | 84.2 M | 84.2 M | 63 M | 63 M | 63 M | 63 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 155 M | 15.5 M | 69.9 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioNTech SE
BNTX
|
2.76 B | $ 91.28 | 0.11 % | $ 27.2 B |  Germany |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M | Germany |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
19.6 M | $ 3.54 | -20.81 % | $ 238 B | Britain |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 330.34 | 3.6 % | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
7.24 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Evogene Ltd.
EVGN
|
25 M | $ 0.79 | 1.22 % | $ 27.9 M |  Israel |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
argenx SE
ARGX
|
1.36 B | $ 748.25 | 0.25 % | $ 25 B |  Niderland |
 |
Завод ДИОД
DIOD
|
195 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
1.04 B | - | - | - | Russia |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.89 | -4.33 % | $ 4.85 M | China |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Teligent, Inc.
TLGT
|
198 M | - | -13.85 % | $ 16.1 M | USA |
 |
AbbVie
ABBV
|
97.3 B | $ 206.69 | -1.01 % | $ 366 B | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Viela Bio, Inc.
VIE
|
47.4 M | - | - | $ 2.91 B | USA |
 |
AbCellera Biologics
ABCL
|
390 M | $ 3.39 | -3.69 % | $ 1.01 B | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
57.2 M | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Ardelyx
ARDX
|
335 M | $ 5.97 | 0.51 % | $ 1.44 B | USA |
 |
Genmab A/S
GMAB
|
2.02 B | $ 27.75 | 0.91 % | $ 17.6 B |  Danmark |
|
Cerevel Therapeutics Holdings
CERE
|
570 M | - | - | $ 7.29 B | USA |
 |
Grifols, S.A.
GRFS
|
12.8 B | $ 8.23 | -0.12 % | $ 6.83 B |  Spain |
 |
Akebia Therapeutics
AKBA
|
344 M | $ 1.32 | -4.35 % | $ 339 M | USA |